CytomX Therapeutics develops cancer treatments using its PROBODY masked biologics platform. CTMX reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 13 | JP Morgan | Target lowered | Buy | |
| Aug 10 | Guggenheim | Maintained | Buy | |
| Mar 16 | JP Morgan | Upgrade | Buy |
Whale Options Flow
90DNo whale options trades in CTMX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTMX is in one of them and how their past CTMX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CTMX in an article yet. Here's the latest on the wider market.
About CytomX Therapeutics
CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments. It uses its PROBODY platform to build masked biologic therapies, which are designed to bind more selectively within tumors and limit effects on healthy tissue. Its most advanced candidate, Varsetatug Masetecan, is an antibody drug conjugate being studied in colorectal cancer, with plans to test it in other solid tumors. The company's therapies are aimed at cancer patients.
- Headquarters
- South San Francisco, CA